[181 Pages Report] The Computational Biology Market size was estimated at USD 6.25 billion in 2023 and expected to reach USD 7.42 billion in 2024, at a CAGR 18.91% to reach USD 21.01 billion by 2030.
Computational biology is an interdisciplinary domain that applies techniques from computer science, applied mathematics, statistics, and bioinformatics to solve complex problems in biology, understand biological data, and model biological systems. It encompasses the development and application of theoretical methods and data-analytical, computational simulation techniques, and mathematical modeling to the study of biological, behavioral, and social systems. The primary aim of this technology is to generate insights into the principles and dynamics of biological systems, as well as to predict their behaviors and interactions. Computational biology is closely related to the field of bioinformatics but tends to focus more on the development of theoretical approaches and computational models. The computational biology market is driven by the increasing need for drug discovery and personalized medicine, advancements in the field of bioinformatics, and the rise in the volume of complex biological data. Government and private funding for research and development in genomics and proteomics also support the market expansion. Despite growth prospects, the need for specialized computational infrastructure, high costs associated with computational tools, and a shortage of skilled professionals to analyze biological data hinder the scope of computational biology. Moreover, concerns regarding data security and privacy and the complexity of regulatory compliances for healthcare-related data create hurdles in market proliferation. However, an integration of artificial intelligence and machine learning algorithms is further presenting lucrative opportunities for market growth by enhancing predictive modeling and data analysis capabilities. Moreover, the rising focus on biomarker discovery and its role in precision medicine opens up new opportunities for the market's expansion.
The computational biology market in the Americas, particularly in North America, is exhibiting robust growth. The presence of established pharmaceutical companies, sophisticated healthcare infrastructure, and rigorous research and development activities are propelling the region's market expansion. Large-scale investments in genomics and proteomics are further spurring demand for computational biology solutions. The United States remains at the forefront, backed by supportive government policies, substantial academic-industry collaborations, and an increase in bioinformatics-related courses that supply skilled professionals to the field. The EMEA region has been experiencing a significant surge in the computational biology market owing to increased funding by private and public entities, particularly in Europe. Efficient regulatory frameworks for drug development and a tradition of excellence in scientific research are driving the market's progress in this region. Germany, the UK, and France are major contributors with their strong focus on biotechnology and computational sciences. The Middle East is steadily catching up, largely due to strategic government investments in the biotech sector, while Africa is in the early stages of development. Asia-Pacific is emerging as a dynamic growth hub for the computational biology market. Rapid economic development, increasing healthcare expenditure, and a burgeoning biotechnology industry characterize the market landscape. Countries in the region are providing lucrative opportunities for market players owing to governmental backing, a focus on education and research in the life sciences, and a rising emphasis on personalized medicine. Cross-border collaborations and the inflow of foreign investments are further defining this market, positioning APAC as a competitive and high-potential region.
In the dynamic field of computational biology, contract based services stand out as a flexible solution for organizations seeking specialized expertise without the overhead of full-time employment. These services, offered by external providers or individual consultants, are tailored to meet the specific project demands and timelines, making them an invaluable resource for companies that require advanced analytical skills, state-of-the-art algorithm development, or custom bioinformatics software solutions on a temporary or per-project basis. In contrast, in-house computational biology services are integrated within an organization's permanent operational structure. This approach allows for a consistent and long-term investment in computational biology expertise, fostering a deep understanding of the company's specific research areas and methodologies. In-house teams are intimately familiar with the data, objectives, and processes of their organization, enabling them to align their output closely with the strategic goals of the business. They provide a stable and continually evolving resource capable of adapting to the company's changing needs over time.
Cellular biological simulation involves the use of computational models to simulate the behaviors and interactions of biological cells. These simulations help to understand and predict cellular functions, biological behaviors, and responses to various stimuli, which is critical for both basic research and applied biomedical applications. The technology is especially relevant for investigating complex biochemical pathways and in silico experimentation, which can be cost-prohibitive or technically challenging to perform in vitro or in vivo. Clinical trials are experimental research studies conducted to determine the efficacy of new drugs, medical devices, or treatment protocols on human subjects. Computational biology plays a pivotal role in the design and analysis of clinical trials, improving the efficiency of trial designs, patient stratification, and data analysis. Drug discovery & disease modeling are crucial applications of computational biology where computer-aided design (CAD) for drug compounds and modeling of disease pathways accelerate the discovery of new therapeutics. These methods enable the exploration of vast chemical spaces and the modeling of complex diseases, respectively, to identify potential targets and molecules for new drugs. Human body simulation software encompasses a broad set of computational tools designed to model anatomical and physiological aspects of the human body. These simulations are employed for a variety of applications, including medical device design, surgical planning, and educational purposes. Preclinical drug development is the phase of research that precedes clinical trials in the drug development process. It involves the use of in silico models and simulation tools to predict the pharmacokinetics, pharmacodynamics, and toxicity of candidate drugs.
In academic settings, computational biology tools are primarily used for research and educational purposes. The emphasis is on accessibility to cutting-edge technology, ease of use for students and researchers, and cost-effectiveness. Academic institutions often require extensive databases and computational power for diverse research ranging from evolutionary biology to systems biology. Commercial entities, including pharmaceutical and biotech companies, prioritize the application of computational biology for drug discovery and development, personalized medicine, and agrigenomics. These sectors seek robust, scalable solutions with a strong emphasis on data security and intellectual property protection.
The market dynamics represent an ever-changing landscape of the Computational Biology Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Computational Biology Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Computational Biology Market.
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Computational Biology Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
The value chain of the Computational Biology Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.
The pricing analysis comprehensively evaluates how a product or service is priced within the Computational Biology Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Computational Biology Market.
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Computational Biology Market.
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Computational Biology Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.
The trade analysis of the Computational Biology Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.
The regulatory framework analysis for the Computational Biology Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Computational Biology Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Computational Biology Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
New Funds Available for Early Career Canadian Researchers Building Careers in Bioinformatics, Computational Biology, or Health Data Sciences
Genome Canada announced its collaboration with the Canadian Institutes of Health Research (CIHR), specifically with the Institutes of Aging, Cancer Research, Genetics, Infection and Immunity, and Musculoskeletal Health and Arthritis, in launching the 2024/25 Health Research Training Platform (HRTP). This initiative, bolstered by partnerships with the Centre for Research on Pandemic Preparedness and Health Emergencies and Mitacs, aims to nurture a diverse group of trainees and early career researchers through interdisciplinary training platforms. With a commitment of USD 6,050,000 for the bioinformatics, computational biology, and health data sciences pool, these funds are dedicated to offering substantial support to a single project that demonstrates potential for profound impact. [Published On: 2023-10-13]
Pluto Announces USD 3.7M Seed Round, Led by Silverton Partners
Pluto announced a significant milestone with the completion of a USD 3.7 million seed financing round, led by Silverton Partners, aimed at propelling the evolution of biological data assessment and multiplying the pace of discoveries within the life sciences domain globally. Boasting an intuitive web-based interface, Pluto's computational biology platform is at the forefront of enhancing researcher capability in the analysis, visualization, and interpretation of complex biological information. [Published On: 2023-05-02]
Accenture Invests in Ocean Genomics to Accelerate AI-driven Drug Discovery and the Development of Personalized Medicines
Accenture PLC has strategically enhanced its technological footprint through an investment in Ocean Genomics via Accenture Ventures' Project Spotlight. Ocean Genomics specializes in computational platforms powered by artificial intelligence, revolutionizing the biopharmaceutical sector's approach to diagnostics and drug development. Their innovative solutions delve into the intricate world of mRNA, enabling the prediction of individual responses to medical treatments with greater accuracy. [Published On: 2023-02-16]
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Computational Biology Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
The report delves into recent significant developments in the Computational Biology Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BGI Group, Biomax Informatics AG, Chemical Computing Group Inc., Compugen Ltd., Dassault Systèmes SE, DNAnexus, Inc., DNASTAR, Inc., Eurofins Scientific SE, Genedata AG, Illumina, Inc., Insilico Medicine, Instem Group, Nimbus Discovery Llc, Ocean Genomics, PerkinElmer, Inc., Pluto Bioinformatics, ProFound Therapeutics, QIAGEN N.V., Rosa & Co. Llc, Schrodinger, Inc., Simulation Plus Inc., SOPHiA GENETICS, Thermo Fisher Scientific Inc., Waters Corporation, and WuXi NextCODE.
This research report categorizes the Computational Biology Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Services
- Contract
- In-house
- Application
- Cellular Biological Simulation
- Clinical Trials
- Drug Discovery & Disease Modelling
- Human Body Simulation Software
- Preclinical Drug Development
- End-Use
- Academics
- Commercial
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Computational Biology Market, by Services
- Computational Biology Market, by Application
- Computational Biology Market, by End-Use
- Americas Computational Biology Market
- Asia-Pacific Computational Biology Market
- Europe, Middle East & Africa Computational Biology Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 22]
- List of Tables [Total: 286]
- List of Companies Mentioned [Total: 26]
Computational biology is the science that gives answer to the question, “How can we learn and use models & algorithms of biological systems constructed from experimental measurements?”
Improvements in drug development processes continuously reduce the time required for a formulation to go from being a candidate to becoming a market-ready product. Speed is especially important in cases such as the development of the COVID-19 vaccine.
The process of drug development requires intensive research, analytics, and clinical trials while meeting regulatory compliance, resulting in lengthy and complex development processes with high uncertainty in cost. Computational platforms can eliminate these issues and assist drugmakers in end-to-end drug development.
Innovators are also introducing a cloud bioinformatics platform for antibody & peptide screening and drug development. It contains a range of features such as sequence editing and annotation, sample clustering and comparison, database management, workflow automation, and detailed reports.
The ongoing innovations in cloud-based platforms are becoming the cherry on top for scientists to perform phage display panning, automate hybridoma analysis, and much more. In this way, scientists and researchers are able to perform computationally intensive tasks from anywhere and at any time through cloud computing.
Improved Identification of Biomarkers:
One of the essential uses of computational biology in personalized medicine is biomarker identification. Biomarkers refer to biological molecules (such as proteins, DNA, and RNA) that point to a particular disease or condition. Genomics and proteomics research rely heavily on computational biology to identify potential biomarkers and understand their functions. Unlike traditional laboratory techniques, computational biology can analyze vast amounts of data accurately, thus identifying biomarkers with higher precision. Once the biomarker is identified, clinicians can develop personalized treatments tailored to an individual's unique genetic makeup.
Drug Discovery and Development:
Computational biology also plays a significant role in drug discovery and development. Traditional laboratory experiments are often time-consuming and expensive, requiring many resources, such as chemicals and human trials. However, using computational biology models, simulations, and artificial intelligence, researchers can predict the effectiveness of a drug faster and cheaper. This technology speeds up the drug discovery process, benefiting patients who depend on these drugs.
Understanding Disease Mechanisms:
Computational biology helps researchers and clinicians better understand a disease's complexity and underlying mechanisms. It enables the integration of large volumes of genomic, proteomic, and metabolomic data, providing a comprehensive view of the disease. It allows clinicians to pinpoint specific genes and proteins contributing to a condition, thus developing personalized treatments addressing the disease's underlying cause. Computational biology, therefore, facilitates the development of individualized medicine, ensuring better outcomes for patients.
Predictive Diagnostics:
In addition to identifying biomarkers and understanding the mechanisms of diseases, computational biology can predict an individual's risk of specific diseases. Predictive models can identify individuals at risk of developing a disease by analyzing a patient's medical history, genomic data, and other relevant data sets. Clinicians can then implement preventive measures, such as preventative medication and lifestyle changes, to mitigate the disease's development.
Precision Oncology:
Computational biology is helping drive the current trend of precision oncology, where clinicians tailor cancer treatments to a person's genes, proteins, and other biomarkers. By analyzing genomic data and other biomarkers in cancer patients, clinicians can focus on identifying specific mutations that drive cancer development. Precision oncology offers a more targeted and effective approach to treating cancer, offering patients better health outcomes.
Computational biology is transforming the way healthcare providers diagnose, treat, and prevent diseases. Personalized medicine, a rapidly growing field, relies on computational biology to identify biomarkers, predict diseases, develop targeted treatments, and understand disease mechanisms. By integrating artificial intelligence and data analytics, clinicians and researchers can gain insights into vast genomic and proteomic data volumes, leading to more effective and individualized treatments. Computational biology will continue to play an essential role in transforming medicine, ensuring better outcomes for patients.
- How big is the Computational Biology Market?
- What is the Computational Biology Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?